Monika Brüggemann
A5075073484- Acute Lymphoblastic Leukemia research
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Chronic Myeloid Leukemia Treatments
- CAR-T cell therapy research
- Acute Myeloid Leukemia Research
- Immunodeficiency and Autoimmune Disorders
- Cancer Genomics and Diagnostics
- X-ray Diffraction in Crystallography
- Childhood Cancer Survivors' Quality of Life
- Crystallization and Solubility Studies
- Monoclonal and Polyclonal Antibodies Research
- Viral-associated cancers and disorders
- Immune Cell Function and Interaction
- Hematopoietic Stem Cell Transplantation
- Health Systems, Economic Evaluations, Quality of Life
- Epigenetics and DNA Methylation
- T-cell and B-cell Immunology
- Single-cell and spatial transcriptomics
- Biomedical Ethics and Regulation
- Multiple Myeloma Research and Treatments
- Crystallography and molecular interactions
- Glycosylation and Glycoproteins Research
- RNA modifications and cancer
- Molecular Biology Techniques and Applications
University Hospital Schleswig-Holstein
2016-2025
University of Lübeck
2016-2025
Kiel University
2016-2025
Integrated Oncology (United States)
2023-2024
Deutsche Forschungsgemeinschaft
2022-2024
Heinrich Heine University Düsseldorf
2024
Düsseldorf University Hospital
2024
Odense University Hospital
2023
University Hospital Cologne
2023
University of Duisburg-Essen
2023
Blinatumomab, a bispecific monoclonal antibody construct that enables CD3-positive T cells to recognize and eliminate CD19-positive acute lymphoblastic leukemia (ALL) blasts, was approved for use in patients with relapsed or refractory B-cell precursor ALL on the basis of single-group trials showed efficacy manageable toxic effects.In this multi-institutional phase 3 trial, we randomly assigned adults heavily pretreated ALL, 2:1 ratio, receive either blinatumomab standard-of-care...
Blinatumomab, a bispecific single-chain antibody targeting the CD19 antigen, is member of novel class antibodies that redirect T cells for selective lysis tumor cells. In acute lymphoblastic leukemia (ALL), persistence or relapse minimal residual disease (MRD) after chemotherapy indicates resistance to and results in hematologic relapse. A phase II clinical study was conducted determine efficacy blinatumomab MRD-positive B-lineage ALL.Patients with MRD induction consolidation therapy were...
Most consensus leukemia & lymphoma antibody panels consist of lists markers based on expert opinions, but they have not been validated. Here we present the validated EuroFlow 8-color for immunophenotyping hematological malignancies. The single-tube screening and multi-tube classification fit into diagnostic algorithm with entries defined by clinical laboratory parameters. were constructed in 2-7 sequential design-evaluation-redesign rounds, using novel Infinicyt software tools multivariate...
Patients with relapsed or refractory acute lymphoblastic leukemia (ALL) have a dismal prognosis. CD19 is homogenously expressed in B-precursor ALL and can be targeted by the investigational bispecific T cell-engager antibody blinatumomab. A phase II trial was performed to determine clinical activity this patient cohort.Thirty-six patients were treated blinatumomab cycles of 4-week continuous infusion followed 2-week treatment-free interval single-arm study dose-finding stage an extension...
Amplicon-based next-generation sequencing (NGS) of immunoglobulin (IG) and T-cell receptor (TR) gene rearrangements for clonality assessment, marker identification quantification minimal residual disease (MRD) in lymphoid neoplasms has been the focus intense research, development application. However, standardization validation a scientifically controlled multicentre setting is still lacking. Therefore, IG/TR assay design, including bioinformatics, was performed within EuroClonality-NGS...
Randomized trials of venetoclax plus anti-CD20 antibodies as first-line treatment in fit patients (i.e., those with a low burden coexisting conditions) advanced chronic lymphocytic leukemia (CLL) have been lacking. Download PDF the Research Summary. In phase 3, open-label trial, we randomly assigned, 1:1:1:1 ratio, CLL who did not TP53 aberrations to receive six cycles chemoimmunotherapy (fludarabine–cyclophosphamide–rituximab or bendamustine–rituximab) 12 venetoclax–rituximab,...
Abstract Chromosomal rearrangements of the human KMT2A/MLL gene are associated with de novo as well therapy-induced infant, pediatric, and adult acute leukemias. Here, we present data obtained from 3401 leukemia patients that have been analyzed between 2003 2022. Genomic breakpoints within KMT2A involved translocation partner genes (TPGs) -partial tandem duplications (PTDs) were determined. Including published literature, a total 107 in-frame fusions identified so far. Further 16...
Blinatumomab is a BiTE® (bispecific T-cell engager) molecule that redirects CD3
In the primary analysis report of GAIA/CLL13 trial, we found that venetoclax-obinutuzumab and venetoclax-obinutuzumab-ibrutinib improved undetectable measurable residual disease (MRD) rates progression-free survival compared with chemoimmunotherapy in patients previously untreated chronic lymphocytic leukaemia. However, to our knowledge, no data on direct comparisons different venetoclax-based combinations are available.